Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Synthetic Salmon Calcitonin

Synthetic Salmon Calcitonin Synthetic salmon calcitonin was given daily for 90 days as a subcutaneous dose of 50 Medical Research Council units to three patients with active Paget's disease and one patient with osteogenesis imperfecta. Symptomatic improvement occurred in two of the patients with Paget's disease and in the patient with osteogenesis imperfecta. During the three months of treatment, serum alkaline phosphatase, urinary hydroxyproline, and urinary calcium decreased significantly in the patients with Paget's disease, and, in the patient with osteogenesis imperfecta, urinary hydroxyproline decreased, suggesting that this new form of calcitonin is also effective in reducing bone resorption in these diseases. No adverse reactions were observed in our initial studies. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Loading next page...
 
/lp/american-medical-association/synthetic-salmon-calcitonin-7kXKgQFxZr

References (21)

Publisher
American Medical Association
Copyright
Copyright © 1972 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.1972.03200230015004
Publisher site
See Article on Publisher Site

Abstract

Synthetic salmon calcitonin was given daily for 90 days as a subcutaneous dose of 50 Medical Research Council units to three patients with active Paget's disease and one patient with osteogenesis imperfecta. Symptomatic improvement occurred in two of the patients with Paget's disease and in the patient with osteogenesis imperfecta. During the three months of treatment, serum alkaline phosphatase, urinary hydroxyproline, and urinary calcium decreased significantly in the patients with Paget's disease, and, in the patient with osteogenesis imperfecta, urinary hydroxyproline decreased, suggesting that this new form of calcitonin is also effective in reducing bone resorption in these diseases. No adverse reactions were observed in our initial studies.

Journal

JAMAAmerican Medical Association

Published: Sep 4, 1972

There are no references for this article.